the stent of choice in acs patients the stent of choice in acs 1) the rationale…
TRANSCRIPT
The Stent of Choice in
ACS patients
The Stent of Choice in ACS
1) The Rationale…
1) The Rationale:
Titanium-Nitride-Oxide Coating
• Absolute Lowest Thrombogenicity• Effective Restenosis Reduction
• Shortest DAP Therapy
Helicoidal Design
• Improved Trackability & Crossability
The Stent of Choice in ACS
The Stent of Choice in ACS
2) The Clinical Evidence…
Titan2 vs. The Latest DES Generation
The BASE-ACS Randomized Trial
BAS vs EES12-Month Clinical Follow-Up
TiTAN-2 XIENCE-V
SOURCE: The BASE-ACS Randomized Controlled Trial Late Breaking Trial EuroPCR 2011
The BASE-ACS Randomized Trial
ACS Population
827 Patients
100% Patients Follow-UpSOURCE: The BASE-ACS Randomized Controlled Trial
Late Breaking Trial EuroPCR 2011
Titan2 vs. The Latest DES Generation
The BASE-ACS RCT
MACE @ 12 months
MACE: Cardiac Death, nonfatal MI or TLR
7.2%
2.6%
6.8%3.9%
TITAN-2
XIENCE-V
%
1 6 120
5
10
15
2.6%
7.2%9.6%
3.9% 6.8%9.0%
Titan-2 BAS (n=417)Xience-V EES (n=410)
Months after Index Procedure
% Pnon-inferiority = 0.001HR 0.94 (0.59-1.50)
TiTAN2 is Non-Inferior
to XIENCE V at 12 months
BAS EES0
5
10
15
20
9.6% 9.0%
The BASE-ACS RCT
MAC
E (%
)
Pnon-inferiority = 0.001
TiTAN-2 XIENCE-V
The BASE-ACS Randomized Trial
BAS vs EES18-Month Clinical Follow-Up
TiTAN-2 XIENCE-V
SOURCE: The BASE-ACS Randomized Controlled Trial Late Breaking Trial ASIA PCR 2012
The BASE-ACS RCT
MACE: Cardiac Death, nonfatal MI or TLR
7.2%
2.6%
6.8%3.9%
TITAN-2
XIENCE-V
%
1 6 120
5
10
15
2.6%
7.2%
9.6%
3.9%6.8%
9.0%
Titan-2 BAS (n=417)Xience-V EES (n=410)
%
MACE @ 18 months
Months after Index Procedure
The BASE-ACS RCT
MACE @ 18 months
MACE: Cardiac Death, nonfatal MI or TLR
7.2%
2.6%
6.8%3.9%
Days after Index Procedure
TITAN-2
XIENCE-V
%
1 6 12 180
5
10
15
2.6%
7.2%
9.6%
3.9%6.8%
9.0%
Titan-2 BAS (n=417)Xience-V EES (n=410)
%
Months after Index Procedure
11.7%
10.8%
P = 0.74HR 0.96 (0.78-1.18)
TiTAN2 vs. XIENCE V
at 18 months
BAS EES0
5
10
15
20
10.8%11.7%
The BASE-ACS RCT
MACE (%)
P =
0.7
4
BAS EES0
5
10
15
20
2.6%
6.3%
BAS EES0
5
10
15
20
1.2%3,7%P
= 0
.01
P =
0.0
21
* Definite & Probable
AMI (%) *Thrombosis (%)
TiTAN-2 XIENCE-V TiTAN-2 XIENCE-V TiTAN-2 XIENCE-V
The BASE-ACS RCT
Titan2 vs. The Latest DES Generation
* Definite & Probable
At 12 months Titan-2 BAS demonstrates its Non-Inferiority vs.Xience-V EES in terms of MACE (9.6% vs 9.0%) in patients with ACS
At 18 months Titan2-BAS improves its MACE score vs. EES
(10.8% vs. 11.7%) due to a significantly better safety profile in terms of hard clinical endpoints:
• AMI (2.6% vs. 6.3%, p=0.01) • Thrombosis* (1.2% vs. 3.7%, p=0.021)
(with significantly less DAPT duration: 8.7 vs.10.2 months, p<0.001)
The Evidence-Based Choice for Your
ACS patients !
All cited trademarks are the property of their respective owners.This material is not intended for use in the United-States and certain other countries.Caution: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. ©2012 Hexacath or its affiliates.